Toward Chemo-Free Regimens - What's Next for DLBCL Treatment

Dr. Karr frames sequencing as the central open question as more chemo-light regimens emerge, pointing to the broader trend toward chemotherapy-sparing approaches for older, frailer patients. Both physicians acknowledge that only a randomized trial can clarify how much the remaining chemotherapy backbone contributes to efficacy. Dr. Kalantri emphasizes quality of life as a guiding priority, closing on an optimistic but cautious note about a future where clinicians can omit the most toxic elements of DLBCL treatment for elderly, frail patients.